The pipeline keeps inching forward
Adcendo ApS says ADCE-T02, its tissue factor-targeted antibody-drug conjugate, has entered the cohort expansion portion of the Tiffany-01 study in advanced solid tumors. Translation: the company is taking the program from early scouting to a bigger test drive.
Why you should care
Biotech investors don’t usually get rewarded for vibes alone. They want evidence that a drug can keep surviving each clinical checkpoint without face-planting. Moving into cohort expansion suggests the company has seen enough signal to keep enrolling more patients — the kind of progress that can nudge sentiment if the program is one of the company’s key shots on goal.
The biotech version of "keep going"
Think of it like a startup getting invited from the beta waitlist into a larger pilot. It’s not approval, and it’s definitely not revenue, but it does mean the story is still alive and moving.
- ADCE-T02 is designed as a tissue factor-targeted ADC
- The study is Tiffany-01
- The current focus is advanced solid tumors
Big picture
For investors, the takeaway is simple: Adcendo is still advancing one of its core pipeline assets, and in biotech, forward progress can matter almost as much as hard data — at least until the next readout decides whether the applause or the airbags come out.